Table 1. Cell-based therapies tested in pre-clinical trials (Baciguluppi et al., 2008)

Clinical Trial No. of
patients
Disease Cell Type Time of
transplantation
Route of
transplantation
Functional
Outcome
Phase I 12 Basal ganglia infarcts Human NT2/D1 Mean: 27 months Intraparenchymal Some improvement
Phase II 12 Ischaemic/ hemorrhagic Human NT2/D1 Mean: 3.5 years Intraparenchymal Some improvement
Phase I/II 30 Mid cerebral artery infarc Mesenchymal 4–9 weeks Intravenous Improved